全文获取类型
收费全文 | 39973篇 |
免费 | 4352篇 |
国内免费 | 2672篇 |
专业分类
耳鼻咽喉 | 294篇 |
儿科学 | 517篇 |
妇产科学 | 456篇 |
基础医学 | 4715篇 |
口腔科学 | 842篇 |
临床医学 | 5178篇 |
内科学 | 5767篇 |
皮肤病学 | 429篇 |
神经病学 | 1836篇 |
特种医学 | 1454篇 |
外国民族医学 | 17篇 |
外科学 | 4244篇 |
综合类 | 6897篇 |
现状与发展 | 13篇 |
一般理论 | 15篇 |
预防医学 | 2863篇 |
眼科学 | 1331篇 |
药学 | 3961篇 |
56篇 | |
中国医学 | 2412篇 |
肿瘤学 | 3700篇 |
出版年
2024年 | 126篇 |
2023年 | 695篇 |
2022年 | 1475篇 |
2021年 | 2352篇 |
2020年 | 1723篇 |
2019年 | 1475篇 |
2018年 | 1513篇 |
2017年 | 1365篇 |
2016年 | 1269篇 |
2015年 | 1922篇 |
2014年 | 2410篇 |
2013年 | 2246篇 |
2012年 | 3120篇 |
2011年 | 3413篇 |
2010年 | 2179篇 |
2009年 | 1830篇 |
2008年 | 2206篇 |
2007年 | 2143篇 |
2006年 | 2173篇 |
2005年 | 1840篇 |
2004年 | 1343篇 |
2003年 | 1154篇 |
2002年 | 969篇 |
2001年 | 834篇 |
2000年 | 790篇 |
1999年 | 816篇 |
1998年 | 522篇 |
1997年 | 477篇 |
1996年 | 372篇 |
1995年 | 322篇 |
1994年 | 323篇 |
1993年 | 185篇 |
1992年 | 237篇 |
1991年 | 188篇 |
1990年 | 153篇 |
1989年 | 194篇 |
1988年 | 134篇 |
1987年 | 134篇 |
1986年 | 63篇 |
1985年 | 75篇 |
1984年 | 47篇 |
1983年 | 30篇 |
1982年 | 26篇 |
1981年 | 26篇 |
1980年 | 19篇 |
1979年 | 26篇 |
1978年 | 11篇 |
1977年 | 5篇 |
1975年 | 9篇 |
1974年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
21.
Xue Yao Yan Zhang Jian Hao Hui-Quan Duan Chen-Xi Zhao Chao Sun Bo Li Bao-You Fan Xu Wang Wen-Xiang Li Xuan-Hao Fu Yong Hu Chang Liu Xiao-Hong Kong Shi-Qing Feng 《中国神经再生研究》2019,(3)
Ferroptosis is an iron-dependent novel cell death pathway. Deferoxamine, a ferroptosis inhibitor, has been reported to promote spinal cord injury repair. It has yet to be clarified whether ferroptosis inhibition represents the mechanism of action of Deferoxamine on spinal cord injury recovery. A rat model of Deferoxamine at thoracic 10 segment was established using a modified Allen's method. Ninety 8-week-old female Wistar rats were used. Rats in the Deferoxamine group were intraperitoneally injected with 100 mg/kg Deferoxamine 30 minutes before injury. Simultaneously, the Sham and Deferoxamine groups served as controls. Drug administration was conducted for 7 consecutive days. The results were as follows:(1) Electron microscopy revealed shrunken mitochondria in the spinal cord injury group.(2) The Basso, Beattie and Bresnahan locomotor rating score showed that recovery of the hindlimb was remarkably better in the Deferoxamine group than in the spinal cord injury group.(3) The iron concentration was lower in the Deferoxamine group than in the spinal cord injury group after injury.(4) Western blot assay revealed that, compared with the spinal cord injury group, GPX4, xCT, and glutathione expression was markedly increased in the Deferoxamine group.(5) Real-time polymerase chain reaction revealed that, compared with the Deferoxamine group, mRNA levels of ferroptosis-related genes Acyl-CoA synthetase family member 2(ACSF2) and iron-responsive element-binding protein 2(IREB2) were up-regulated in the Deferoxamine group.(6) Deferoxamine increased survival of neurons and inhibited gliosis. These findings confirm that Deferoxamine can repair spinal cord injury by inhibiting ferroptosis. Targeting ferroptosis is therefore a promising therapeutic approach for spinal cord injury. 相似文献
22.
Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) are a new type of drug for the treatment of diabetes, and they have been proven to have a good hypoglycemic effect. Several lines of clinical evidence have shown that SGLT2 inhibitors can significantly reduce the risks of atherosclerosis, hospitalization for heart failure, cardiovascular death, and all-cause mortality and delay the progression of chronic kidney disease. Because of the protective effects of SGLT2 inhibitors on the heart and kidney, they are being studied for the treatment of heart failure and chronic kidney disease in patients without diabetes. Therefore, it is necessary for cardiologists, patients with diabetes, and nephrologists to fully understand this type of drug. In this review, we summarize the following three aspects of SGLT2 inhibitors: the recent clinical evidence of their cardiovascular benefits, their mechanisms of action, and their safety. 相似文献
23.
24.
25.
随着对肿瘤热疗和肿瘤免疫微环境(TIME)的深入研究,近年来热疗对TIME的作用越来越受到学者们的重视。本文就目前国内外研究进展,对热疗与TIME中几类主要免疫细胞和免疫相关细胞因子的影响及作用机制作一综述。全面而透彻的了解热疗对TIME的调控作用,有助于为肿瘤治疗提供新的思路和方法。 相似文献
26.
Yu Fan Xiaoling Liao Yuesong Pan Kehui Dong Yilong Wang Yongjun Wang 《Journal of stroke and cerebrovascular diseases》2019,28(1):220-226
Background
The intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator (rt-PA) therapy is safe and efficient during the treatment of acute ischemic stroke. Nonetheless, the different outcomes among various stroke subgroups have limited data with regard to the safety and efficacy of cryptogenic stroke (CS). The present study compared the safety and efficacy when IVT with rt-PA was used for the treatment of CS and the other stroke subtypes.Methods
This study classified the IVT with rt-PA patients within 4.5 hours after stroke onset, based on the trial of ORG 10172 in acute stroke treatment criteria in terms of diagnostic evaluation. The data were obtained from the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China database, a large multicenter prospective registry. A multivariable logistic regression model was employed to compare the differences between the subtypes in symptomatic intracerebral hemorrhage (sICH) within 7 days and studied the mortality and the outcome during 90 days.Results
In total, 1118 patients were recruited; of these, 131 (11.7%) suffered from CS and 987 (88.3%) with the other etiology. In the CS group, patients were younger than those in the other etiology groups (P < .001). Moreover, it had a lower prevalence of previous stroke (P?=?.0117), receiving antiplatelet drug in 24 hours prior to thrombolysis (P?=?.0017), and functional independence (mRS > 1 before stroke, P?=?.003). The CS group had lower blood pressure (systolic blood pressure P?=?.0001; diastolic blood pressure; P?=?.0212) before thrombolysis, atrial fibrillation (P < .001), and diabetes mellitus (P?=?.0005). Transient ischemic attack, hypertension, hyperlipidemia, blood glucose, receiving anticoagulants in 24 hours prior to thrombolysis, and standard dosage of rt-PA were equally distributed in both groups. After the adjustment of confounders between the CS and the other subgroups, no obvious differences were observed in sICH rate and mortality (P > .05) The CS patients exhibited excellent recovery (mRS, 0-1; 63.78%) and functional independence (mRS, 0-2; 74.8%) than the large artery atherosclerosis patients.Conclusions
IVT with rt-PA is a safe and effective method for the treatment of CS patients. 相似文献27.
范玲 《中华产科急救电子杂志》2020,9(3):133-135
远程胎儿监护是应用互连网及计算机技术,孕妇在家中或远程监护终端将胎心监护图形传输到中央监护站,医生即可通过电脑或手机APP远程判读。对高危孕妇实行远程监护,便于及时发现胎儿宫内缺氧情况和及时处理,改善围产儿结局。 相似文献
28.
目的对中药石莼进行生药学研究,为其质量控制提供依据。方法对石莼基原、采收期、采收加工方法进行考证,建立性状、薄层色谱鉴别方法对其进行定性鉴别。结果明确了石莼药材基原、采收期及采收加工方法;所建立的薄层色谱鉴别方法化学成分信息量丰富,专属性强。结论本研究为中药石莼的鉴别、开发利用及质量标准的制订奠定了基础。 相似文献
29.
肺癌是全球发病率和死亡率最高的恶性肿瘤。近年来,随着新型药物的出现和治疗模式的优化,肺癌患者的预后已有一定改善。新辅助治疗是指对潜在可接受手术切除的患者,先给予术前抗肿瘤治疗后再行手术治疗。新辅助治疗通过术前治疗可以缩小肿瘤体积,降低肿瘤分期;并且可以杀灭患者机体中循环肿瘤细胞及微转移病灶,令患者远期生存获益。靶向治疗及免疫治疗已被应用于晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的一线治疗。因此,有临床试验尝试将以上两种治疗手段应用于早期可切除NSCLC患者的新辅助治疗。本文针对新辅助靶向及免疫治疗对早期可切除NSCLC患者的疗效、治疗中的潜在风险予以综述,并探讨新辅助治疗的未来发展方向。 相似文献
30.
目的探讨专科护士-社区护士-个体-家庭四方联动防跌护理模式在社区跌倒高危老年人中的应用与效果。方法选取深圳市龙岗区的2个社区,随机分为观察组和对照组,从两个社区登记建档的跌倒高风险老年居民中分别随机抽选45名进行干预。观察组采用"专科护士-社区护士-个体-家庭"四方联动推进的综合干预方案。对照组接受社区防跌倒常规护理。于干预前及干预后12个月使用修订版社区老年人跌倒危险评估量表、步态和平衡测试量表对两组老年人进行评测,记录两组1年内跌倒发生例次。结果干预期间跌倒发生情况:观察组1人次,对照组6人次。观察组步态和平衡测试得分提高,跌倒危险评估表得分降低,与对照组比较,差异有统计学意义(均P0.01)。结论四方联动的综合干预方案应用于社区居家老年人,能有效降低老年人跌倒风险,提升其防跌能力,对预防社区老年人跌倒的发生有积极作用。 相似文献